Suppr超能文献

共患阿片类药物使用障碍的兴奋剂使用障碍患者药物治疗的系统评价和荟萃分析。

A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.

机构信息

Division of General Internal Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States; Central City Concern, Portland, OR, United States.

Evidence Synthesis Program Center, VA Portland Health Care System, Portland, OR, United States.

出版信息

Drug Alcohol Depend. 2020 Nov 1;216:108193. doi: 10.1016/j.drugalcdep.2020.108193. Epub 2020 Aug 1.

Abstract

BACKGROUND

Stimulant (cocaine and/or methamphetamine) use has increased among people with opioid use disorder. We conducted a systematic review of medications for stimulant use disorders in this population.

METHODS

We searched for randomized controlled trials in multiple databases through April 2019, and dual-screened studies using pre-specified inclusion criteria. Primary outcomes were abstinence defined as stimulant-negative urine screens for ≥3 consecutive weeks; overall use as the proportion of stimulant-negative urine specimens; and retention as the proportion of participants who completed treatment. We rated strength of evidence using established criteria and conducted meta-analyses of comparable interventions and outcomes.

RESULTS

Thirty-four trials of 22 medications focused on cocaine use disorder in patients with opioid use disorder. Most studies enrolled participants stabilized on opioid maintenence therapy, generally methadone. None of the six studies that assessed abstinence found significant differences between groups. We found moderate-strength evidence that antidepressants (desipramine, bupropion, and fluoxetine) worsened retention. There was moderate-strength evidence that disulfiram worsened treatment retention (N = 605, RR 0.86, 95 % CI 0.77 to 0.95). We found low-strength evidence that psychostimulants (mazindol and dexamphetamine) may reduce cocaine use, though the difference was not statistically significant (standard mean difference 0.35 [95 % CI -0.05 to 0.74]). There was only 1 trial for methamphetamine use disorder, which showed insufficient-strength evidence for naltrexone.

CONCLUSIONS

Co-occurring stimulant/opioid use disorder is an important problem for targeting future research. Medication trials for methamphetamine use disorder are lacking in this population. Most of the medications studied for cocaine use were ineffective, although psychostimulants warrant further study.

摘要

背景

阿片类药物使用障碍患者中兴奋剂(可卡因和/或甲基苯丙胺)的使用有所增加。我们对该人群中兴奋剂使用障碍的药物治疗进行了系统评价。

方法

我们通过多个数据库搜索了截至 2019 年 4 月的随机对照试验,并使用预先规定的纳入标准进行了双重筛选研究。主要结局是连续 3 周以上的尿液兴奋剂阴性定义的禁欲;整体使用率是尿液兴奋剂阴性标本的比例;保留率是完成治疗的参与者的比例。我们使用既定标准评估证据强度,并对可比干预措施和结局进行荟萃分析。

结果

34 项针对阿片类药物使用障碍患者可卡因使用障碍的 22 种药物试验。大多数研究招募的是稳定接受阿片类药物维持治疗的参与者,通常是美沙酮。在评估禁欲的 6 项研究中,没有一项发现组间存在显著差异。我们发现,抗抑郁药(去甲丙咪嗪、安非他酮和氟西汀)会降低保留率,这是中等强度的证据(n = 605,RR 0.86,95%CI 0.77 至 0.95)。我们发现,双硫仑可能会降低治疗保留率,这是中等强度的证据(n = 605,RR 0.86,95%CI 0.77 至 0.95)。我们发现,低强度证据表明,苯丙胺类兴奋剂(mazindol 和右旋苯丙胺)可能会减少可卡因的使用,但差异无统计学意义(标准均数差 0.35 [95%CI -0.05 至 0.74])。只有 1 项针对甲基苯丙胺使用障碍的试验,结果表明纳曲酮的证据强度不足。

结论

并发的兴奋剂/阿片类药物使用障碍是未来研究的一个重要问题。在该人群中,针对甲基苯丙胺使用障碍的药物试验缺乏。虽然苯丙胺类兴奋剂值得进一步研究,但大多数用于可卡因使用障碍的药物治疗都无效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d4/8562993/f8ab111c98db/nihms-1617901-f0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验